Caliway Biopharmaceuticals Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Yufang Ling

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

CEO

Yufang Ling

no data

Permanencia

Ms. Yufang Ling serves as CEO and R&D Chief of Caliway Biopharmaceuticals Co. Ltd. She holds a master's degree from the Institute of Biochemistry and Molecular Biology, National Cheng Kung University Schoo...

Caliway Biopharmaceuticals Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Caliway Biopharmaceuticals Co., Ltd., Annual General Meeting, Jun 24, 2024

Recent updates

Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints

Caliway Biopharmaceuticals Co., Ltd., Annual General Meeting, Jun 24, 2024

New minor risk - Share price stability

Full year 2023 earnings released: NT$3.94 loss per share (vs NT$4.89 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Shareholder dilution

Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease

Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

New major risk - Revenue and earnings growth

Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease

Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding

Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7

First half 2023 earnings released

Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite

Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction

CEO

Permanencia